A Phase 1 Clinical Trial of CHT-25 a 1131l-Labeled Chimeric Anti-CD25Antibody Showing Efficacy in Patients with Refractory Lymphoma

G Dancey, J. Violet, A.J. Malaroda, S.K. Sharma, Roslyn Francis, S. Othman, S. Parker, J. Buscombe, N. Griffen, P. Chan, A. Malhotra, N. Woodward, A. Ramsay, P. Ross, T.A. Lister, P. Amlot, R. Begent, C. Mcnamara

    Research output: Contribution to journalArticle

    24 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)7701-7710
    JournalClinical Cancer Research
    Volume15
    DOIs
    Publication statusPublished - 2009

    Cite this

    Dancey, G ; Violet, J. ; Malaroda, A.J. ; Sharma, S.K. ; Francis, Roslyn ; Othman, S. ; Parker, S. ; Buscombe, J. ; Griffen, N. ; Chan, P. ; Malhotra, A. ; Woodward, N. ; Ramsay, A. ; Ross, P. ; Lister, T.A. ; Amlot, P. ; Begent, R. ; Mcnamara, C. / A Phase 1 Clinical Trial of CHT-25 a 1131l-Labeled Chimeric Anti-CD25Antibody Showing Efficacy in Patients with Refractory Lymphoma. In: Clinical Cancer Research. 2009 ; Vol. 15. pp. 7701-7710.
    @article{37a5fb25077b4c388416bd591c0e6d2f,
    title = "A Phase 1 Clinical Trial of CHT-25 a 1131l-Labeled Chimeric Anti-CD25Antibody Showing Efficacy in Patients with Refractory Lymphoma",
    author = "G Dancey and J. Violet and A.J. Malaroda and S.K. Sharma and Roslyn Francis and S. Othman and S. Parker and J. Buscombe and N. Griffen and P. Chan and A. Malhotra and N. Woodward and A. Ramsay and P. Ross and T.A. Lister and P. Amlot and R. Begent and C. Mcnamara",
    year = "2009",
    doi = "10.1158/1078-0432.CCR-09-1421",
    language = "English",
    volume = "15",
    pages = "7701--7710",
    journal = "Clinical Cancer Reserach",
    issn = "1078-0432",
    publisher = "American Association for Cancer Research Inc.",

    }

    Dancey, G, Violet, J, Malaroda, AJ, Sharma, SK, Francis, R, Othman, S, Parker, S, Buscombe, J, Griffen, N, Chan, P, Malhotra, A, Woodward, N, Ramsay, A, Ross, P, Lister, TA, Amlot, P, Begent, R & Mcnamara, C 2009, 'A Phase 1 Clinical Trial of CHT-25 a 1131l-Labeled Chimeric Anti-CD25Antibody Showing Efficacy in Patients with Refractory Lymphoma' Clinical Cancer Research, vol. 15, pp. 7701-7710. https://doi.org/10.1158/1078-0432.CCR-09-1421

    A Phase 1 Clinical Trial of CHT-25 a 1131l-Labeled Chimeric Anti-CD25Antibody Showing Efficacy in Patients with Refractory Lymphoma. / Dancey, G; Violet, J.; Malaroda, A.J.; Sharma, S.K.; Francis, Roslyn; Othman, S.; Parker, S.; Buscombe, J.; Griffen, N.; Chan, P.; Malhotra, A.; Woodward, N.; Ramsay, A.; Ross, P.; Lister, T.A.; Amlot, P.; Begent, R.; Mcnamara, C.

    In: Clinical Cancer Research, Vol. 15, 2009, p. 7701-7710.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A Phase 1 Clinical Trial of CHT-25 a 1131l-Labeled Chimeric Anti-CD25Antibody Showing Efficacy in Patients with Refractory Lymphoma

    AU - Dancey, G

    AU - Violet, J.

    AU - Malaroda, A.J.

    AU - Sharma, S.K.

    AU - Francis, Roslyn

    AU - Othman, S.

    AU - Parker, S.

    AU - Buscombe, J.

    AU - Griffen, N.

    AU - Chan, P.

    AU - Malhotra, A.

    AU - Woodward, N.

    AU - Ramsay, A.

    AU - Ross, P.

    AU - Lister, T.A.

    AU - Amlot, P.

    AU - Begent, R.

    AU - Mcnamara, C.

    PY - 2009

    Y1 - 2009

    U2 - 10.1158/1078-0432.CCR-09-1421

    DO - 10.1158/1078-0432.CCR-09-1421

    M3 - Article

    VL - 15

    SP - 7701

    EP - 7710

    JO - Clinical Cancer Reserach

    JF - Clinical Cancer Reserach

    SN - 1078-0432

    ER -